Ascendis Pharma A/S Target Price

Where could ASND trade next? Consensus target price: $310.

Get informed when a big investor buys or sells

+ Follow

Share Price

$257.93

Average Target Price

$309.94

20.2% upside

17 analysts in the last 4 months

High: $345 | Low: $268

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-10-26	Canaccord Genuity	$268	3.9% upside
2026-10-15	UBS	$269	4.3% upside
2026-09-16	UBS	$344	33.4% upside
2026-09-15	Raymond JamesMartin Auster	$287	11.3% upside
2026-09-10	H.C. Wainwright	$344	33.4% upside
2026-09-01	OppenheimerLeland Gershell	$312	21% upside
2026-09-01	Morgan StanleyMaxwell Skor	$273	5.8% upside
2026-08-31	Jefferies	$330	27.9% upside
2026-08-31	Stifel Nicolaus	$326	26.4% upside
2026-08-31	UBS	$345	33.8% upside
2026-08-27	H.C. Wainwright	$345	33.8% upside
2026-08-18	BMO Capital	$319	23.7% upside
2026-08-14	RBC CapitalLuca Issi	$290	12.4% upside
2026-08-14	Barclays	$329	27.6% upside
2026-08-13	JefferiesKelly Shi	$333	29.1% upside
2026-07-23	Morgan Stanley	$275	6.6% upside
2026-07-07	RBC Capital	$280	8.6% upside
2026-05-15	Evercore ISI	$329	27.6% upside
2026-05-11	Barclays	$345	33.8% upside
2026-05-08	Wells Fargo	$326	26.4% upside
2026-03-05	Jefferies	$262	1.6% upside
2026-03-04	Stifel NicolausAlex Thompson	$332	28.7% upside
2026-03-02	Wolfe ResearchKalpit Patel	$260	0.8% upside
2026-03-02	Cantor FitzgeraldLi Watsek	$300	16.3% upside
2026-03-02	Evercore ISIJosh Schimmer	$324	25.6% upside
2026-03-02	Goldman SachsPaul Choi	$255	1.1% downside
2026-02-12	Wedbush	$273	5.8% upside
2026-02-12	Oppenheimer	$262	1.6% upside
2026-02-12	Stifel NicolausAlex Thompson	$325	26% upside
2026-02-12	Morgan StanleyMaxwell Skor	$256	0.7% downside
2026-01-27	BarclaysEliana Merle	$342	32.6% upside
2026-01-20	RBC Capital	$250	3.1% downside
2026-01-20	Wells FargoDerek Archila	$330	27.9% upside
2026-01-09	Wells Fargo	$322	24.8% upside
2025-12-11	Stifel NicolausAlex Thompson	$256	0.7% downside
2025-10-13	Cantor FitzgeraldLi Watsek	$254	1.5% downside
2025-08-08	RBC CapitalLuca Issi	$230	10.8% downside
2025-02-18	Morgan Stanley	$180	30.2% downside
2024-09-23	Bank of America SecuritiesTazeen Ahmad	$191	25.9% downside
2024-09-17	Evercore ISIGavin Clark-Gartner	$205	20.5% downside
2024-09-17	OppenheimerLeland Gershell	$190	26.3% downside
2024-09-17	CitigroupDavid Lebowitz	$207	19.7% downside
2024-09-17	Wells FargoDerek Archila	$289	12% upside
2024-09-16	Bank of America SecuritiesTazeen Ahmad	$175	32.2% downside
2024-09-16	Goldman SachsPaul Choi	$200	22.5% downside
2024-09-13	CitigroupDavid Lebowitz	$178	31% downside
2024-09-05	OppenheimerLeland Gershell	$180	30.2% downside
2024-08-13	JefferiesKelly Shi	$196	24% downside
2024-05-30	Stifel NicolausAlex Thompson	$200	22.5% downside
2024-05-15	Morgan StanleyVikram Purohit	$140	45.7% downside

Ascendis Pharma A/S (ASND) FAQ

The latest target price for ASND is $310. Investors often review this figure alongside Ascendis Pharma A/S's historical trend and sector peers before judging valuation or financial health.

Ascendis Pharma A/S trades near $257.93 while the consensus target sits at $310 (20.2% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting ASND's target price ($310), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Ascendis Pharma A/S's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.